Here’s why this healthcare stock is on our BUY watchlist
The Fifth Person The Fifth Person
43.9K subscribers
14,766 views
0

 Published On Mar 20, 2024

What if you could simply take something and 'magically' lose weight? In this roundtable discussion, we delve into one company that is rapidly making waves in both the U.S. and international weight-loss markets with its weight-loss medication that has received FDA approval.

How big is the global weight-loss market? Can this company's miracle weight-loss drug maintain its lead in the market? How fast is the company expected to grow in the next few years? We discuss all this and more in our latest episode!

📈 OPEN A SAXO ACCOUNT TODAY
https://fifthperson.com/saxo

Saxo now has over 1 million clients and more than US$100 billion in client assets. It is an industry leader with over 70,000 global financial products, with access to 50 exchanges worldwide, supporting over 20 currencies. Saxo has been in Singapore since 2006, and is licensed and regulated by the MAS. Please note that the views on Novo Nordisk are not endorsed by Saxo and should not be constituted as financial and investment advice. This message has not been reviewed by the Monetary Authority of Singapore.

00:00 Introduction
01:00 Business model
09:17 Addressable market
14:15 Financials
17:24 Risks
22:32 Valuation
25:19 Saxo Markets

show more

Share/Embed